ERS 2026: tozorakimab’s groundbreaking exacerbation reduction sets a new bar in COPD
The focus of this latest data presentation was the drug’s efficacy in reducing moderate and severe exacerbations among COPD patients who continued to experience exacerbations despite inhaled standard-of-care therapy.
